

**PERFORMANCE IN DELIVERING CLINICAL RESEARCH – Q2 (2018/19)**



IRAS No	REC No	Name of Trial	Target Number of Patients Agreed	Target Recruitment	Minimum No	Maximum No	Target Date to recruits patient agreed?	Date Agreed to recruit target number of patients	Total Recruited by agreed date	Total of Study Participants Recruited	Date closed to Recruitment	Reason for Closure
225662	17/YH/0116	SUSTAIN-10	Number Agreed	8	8	8	Date Agreed	14/11/2017	19	19	14/11/2017	Recruitment Finished
131006	13/LO/0826	CCRN 2553 (C Diff vaccine)	Number Agreed	25	25	25	Date Agreed	17/11/2017	47	47	17/11/2017	Withdrawn by Sponsor
180533	15/WM/0316	GAST 4608 (Inflammatory Bowel Disease)	Number Agreed	10	10	10	Date Agreed	01/12/2017	18	18	31/10/2017	Recruitment Finished
181394	15/NW/0519	GAST 4560	Number Agreed	20	20	20	Date Agreed	10/09/2015	20	20	29/11/2017	Recruitment Finished
211430	16/EM/0376	RENA 5499	Number Agreed	1	1	1	Date Agreed	31/03/2018	7	7	31/03/2018	Recruitment Finished
198058	17/LO/0064	Study of Mirvetuximab Soravtansine vs standard cancer treatments	Number Agreed	2	2	2	Date Agreed	21/06/2018	1	1	26/04/2018	Recruitment finished
209261	16/SC/0600	Efficacy and Safety of Filgotinib in Active Ulcerative Colitis	Number Agreed	4	4	4	Date Agreed	30/09/2018	0	0	27/07/2018	Withdrawn by host
209260	16/SC/0601	Long Term Safety of Filgotinib in Active Ulcerative Colitis	Number Agreed	3	3	3	Date Agreed	30/11/2019	0	0	27/07/2018	Withdrawn by host
209259	16/SC/0630	Efficacy and Safety of Fligotinib in Active Crohn's Disease	Number Agreed	4	4	4	Date Agreed	31/12/2019	0	0	27/07/2018	Withdrawn by host
209258	16/SC/0631	Long Term Safety of Filgotinib in Active Crohn's Disease	Number Agreed	3	3	3	Date Agreed	30/11/2019	0	0	27/07/2018	Withdrawn by host